Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + etoposide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Cytarabine + etoposide is a combination chemotherapy regimen consisting of two small molecule antineoplastic agents. Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis by acting as an antimetabolite, primarily affecting cells in the S phase of the cell cycle. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks by preventing the religation of double-stranded DNA during replication. This combination has been used as salvage therapy for relapsed or refractory hematologic malignancies such as acute myeloid leukemia (AML) and primary central nervous system lymphoma (PCNSL). The regimen may be referred to as CYVE or EC depending on context[1][6]. Both drugs are administered intravenously, often in high doses, and are associated with significant hematologic toxicity.
- Other names
- CYVEEC (for etoposide and cytarabine)cytarabine and etoposide combination
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cytarabine + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + etoposide.